Home » Market News » DirectorsTalk Highlights » preCISION and Affimer based cancer therapies
Avacta Group Plc

preCISION and Affimer based cancer therapies

In this interview, Alastair Smith discusses our development of a rapid antigen test for SARS-Cov-2 and the progress of our preCISIONTM and Affimer® based cancer therapies. Watch below. 

Source: IG TV

Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.